The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

BAP1  -  BRCA1 associated protein-1 (ubiquitin...

Homo sapiens

Synonyms: BRCA1-associated protein 1, Cerebral protein 6, HUCEP-13, KIAA0272, UCHL2, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BAP1


High impact information on BAP1


Chemical compound and disease context of BAP1


Biological context of BAP1


Anatomical context of BAP1


Associations of BAP1 with chemical compounds

  • In BRCA1 associated tumours receptors for oestrogen and progesterone were expressed less frequently (respectively, P = 0.001 and P = 0.002) than in controls, which is in line with findings from other studies [16].
  • BRCA1-associated tumours appear to show an increased frequency of TP53 mutations, frequent p53 protein stabilization and absence of imunoreactivity for steroid hormone receptors [17].

Regulatory relationships of BAP1


Other interactions of BAP1


Analytical, diagnostic and therapeutic context of BAP1


  1. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Jensen, D.E., Proctor, M., Marquis, S.T., Gardner, H.P., Ha, S.I., Chodosh, L.A., Ishov, A.M., Tommerup, N., Vissing, H., Sekido, Y., Minna, J., Borodovsky, A., Schultz, D.C., Wilkinson, K.D., Maul, G.G., Barlev, N., Berger, S.L., Prendergast, G.C., Rauscher, F.J. Oncogene (1998) [Pubmed]
  2. Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma. Hamilton, L.J., Evans, A.J., Wilson, A.R., Scott, N., Cornford, E.J., Pinder, S.E., Khan, H.N., Macmillan, R.D. Clinical radiology. (2004) [Pubmed]
  3. Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors. Tisserand, P., Fouquet, C., Barrois, M., Gallou, C., Dendale, R., Stoppa-Lyonnet, D., Sastre-Garau, X., Fourquet, A., Soussi, T. Cancer Biol. Ther. (2003) [Pubmed]
  4. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Ladanyi, M., Zauderer, M.G., Krug, L.M., Ito, T., McMillan, R., Bott, M., Giancotti, F. Clin. Cancer Res. (2012) [Pubmed]
  5. Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50. Kleiman, F.E., Manley, J.L. Science (1999) [Pubmed]
  6. CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. Nathanson, K.L., Shugart, Y.Y., Omaruddin, R., Szabo, C., Goldgar, D., Rebbeck, T.R., Weber, B.L. Hum. Mol. Genet. (2002) [Pubmed]
  7. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Xing, D., Orsulic, S. Cancer Res. (2006) [Pubmed]
  8. TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Sinclair, C.S., Adem, C., Naderi, A., Soderberg, C.L., Johnson, M., Wu, K., Wadum, L., Couch, V.L., Sellers, T.A., Schaid, D., Slezak, J., Fredericksen, Z., Ingle, J.N., Hartmann, L., Jenkins, R.B., Couch, F.J. Cancer Res. (2002) [Pubmed]
  9. A common DNA-binding site for SZF1 and the BRCA1-associated zinc finger protein, ZBRK1. Peng, H., Zheng, L., Lee, W.H., Rux, J.J., Rauscher, F.J. Cancer Res. (2002) [Pubmed]
  10. Survival in hereditary breast cancer associated with germline mutations of BRCA2. Verhoog, L.C., Brekelmans, C.T., Seynaeve, C., Dahmen, G., van Geel, A.N., Bartels, C.C., Tilanus-Linthorst, M.M., Wagner, A., Devilee, P., Halley, D.J., van den Ouweland, A.M., Meijers-Heijboer, E.J., Klijn, J.G. J. Clin. Oncol. (1999) [Pubmed]
  11. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Grushko, T.A., Blackwood, M.A., Schumm, P.L., Hagos, F.G., Adeyanju, M.O., Feldman, M.D., Sanders, M.O., Weber, B.L., Olopade, O.I. Cancer Res. (2002) [Pubmed]
  12. Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1. Jensen, D.E., Rauscher, F.J. Cancer Lett. (1999) [Pubmed]
  13. Androgen pathway dysregulation in BRCA1-mutated breast tumors. Berns, E.M., Dirkzwager-Kiel, M.J., Kuenen-Boumeester, V., Timmermans, M., Verhoog, L.C., van den Ouweland, A.M., Meijer-Heijboer, H., Klijn, J.G., van der Kwast, T.H. Breast Cancer Res. Treat. (2003) [Pubmed]
  14. Vascular consequences of subclavian artery transection for the treatment of congenital heart disease. Lodge, F.A., Lamberti, J.J., Goodman, A.H., Kirkpatrick, S.E., George, L., Mathewson, J.W., Waldman, J.D. J. Thorac. Cardiovasc. Surg. (1983) [Pubmed]
  15. Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Jongsma, A.P., Piek, J.M., Zweemer, R.P., Verheijen, R.H., Klein Gebbinck, J.W., van Kamp, G.J., Jacobs, I.J., Shaw, P., van Diest, P.J., Kenemans, P. MP, Mol. Pathol. (2002) [Pubmed]
  16. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. de Bock, G.H., Tollenaar, R.A., Papelard, H., Cornelisse, C.J., Devilee, P., van de Vijver, M.J. Br. J. Cancer (2001) [Pubmed]
  17. The pathology of familial breast cancer: Immunohistochemistry and molecular analysis. Osin, P.P., Lakhani, S.R. Breast Cancer Res. (1999) [Pubmed]
  18. Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Schuyer, M., Berns, E.M. Mol. Cell. Endocrinol. (1999) [Pubmed]
  19. Redistribution of BRCA1 among four different protein complexes following replication blockage. Chiba, N., Parvin, J.D. J. Biol. Chem. (2001) [Pubmed]
  20. Concomitant inactivation of p53 and Chk2 in breast cancer. Sullivan, A., Yuille, M., Repellin, C., Reddy, A., Reelfs, O., Bell, A., Dunne, B., Gusterson, B.A., Osin, P., Farrell, P.J., Yulug, I., Evans, A., Ozcelik, T., Gasco, M., Crook, T. Oncogene (2002) [Pubmed]
  21. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Pharoah, P.D., Easton, D.F., Stockton, D.L., Gayther, S., Ponder, B.A. Cancer Res. (1999) [Pubmed]
  22. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Bonadona, V., Dussart-Moser, S., Voirin, N., Sinilnikova, O.M., Mignotte, H., Mathevet, P., Brémond, A., Treilleux, I., Martin, A., Romestaing, P., Raudrant, D., Rudigoz, R.C., Lenoir, G.M., Lasset, C. Breast Cancer Res. Treat. (2007) [Pubmed]
  23. Surgical advances in the treatment of ovarian cancer. Li, A.J., Karlan, B.Y. Hematol. Oncol. Clin. North Am. (2003) [Pubmed]
WikiGenes - Universities